Mumbai, 04th July, 2025: Alembic Pharmaceuticals, Inc., the U.S. subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics Ltd. (“Utility”) in a $12 million deal to strengthen its presence in the U.S. market. Alembic will begin the commercialization of Utility’s recently FDA approved product Pivya® (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya® was approved by the FDA in […]
The post Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen U.S. footprint first appeared on Business News Week.